Results 191 to 200 of about 1,583,870 (298)
OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC [PDF]
, 2017 Yasir Y. Elamin, Jacqulyne Robichaux, Vincent K. Lam, Anne S. Tsao, Chien‐Hsing Lu, George Blumenschein, Jonathan M. Kurie, Julie R. Brahmer, S. Li, Ting Chen, Adriana Estrada‐Bernal, Anna Truini, Monique B. Nilsson, Anh T. Le, Zhi Tan, Shaozeng Zhang, Robert C. Doebele, Katerina Politi, Zane Yang, S. Liu, Kah Keng Wong, John V. Heymach +21 moreopenalex +1 more sourceIntein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar +9 morewiley +1 more sourceImproving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann +15 morewiley +1 more sourceCytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Molecular Oncology, EarlyView.Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock +10 morewiley +1 more sourceLong-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour
, 2020 Philippe A. Cassier, Antoîne Italiano, Carlos Gomez‐Roca, Christophe Le Tourneau, Maud Toulmonde, Sandra P. D’Angelo, Kristy Weber, Delphine Loirat, Wolfgang Jacob, Anna-Maria Jegg, Francesca Michielin, R D Christen, Carl Watson, Michael A. Cannarile, Irina Klaman, K. Abiraj, Carola H. Ries, Maja Weisser, Dominik Rüttinger, Jean‐Yves Blay, Jean‐Pierre Delord +20 moreopenalex +1 more source
